Clinical settings with tofacitinib in ulcerative colitis

There are aspects of Janus kinase (JAK) inhibitors, specially tofacitinib, that distinguish them from other drugs used in the treatment of ulcerative colitis (UC), such as their oral administration, short half-life, and lack of immunogenicity. With the scientific evidence currently available, we should mention tofacitinib quick action, flexibility of use, and efficacy profile in patients regardless of whether these have previously been exposed to TNF inhibitors (anti-TNF drugs) or other biologic agents. Moreover, their safety profile is known and manageable although certain considerations and precautions should be made before and during treatpertaining to this drug like its use in the event of failure or intolerance to previous treatment with biologic agents concomitant immune-mediated diseases.